Pharmaceutical and biotech executives looking to handicap how their product portfolio would be impacted by a national center on comparative effectiveness should study a cheat sheet provided by a Center for Medicare & Medicaid Services advisory committee last fall. CMS’ Medicare Evidence Development & Coverage Advisory Committee (MedCAC) met in October to provide the agency with "prioritized research topics" in areas of "critical importance" to the Medicare program.
The priority list was created by CMS as part of its existing effort to encourage evidence development in areas of...
